These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 7123546

  • 1. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K, Aoyagi K.
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [Abstract] [Full Text] [Related]

  • 2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K, Imai K, Yamanaka H, Tomaru Y, Kitaura K.
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB, Jeannet C, Depierre D, Courvoisier B.
    Schweiz Med Wochenschr; 1981 Feb 21; 111(8):246-51. PubMed ID: 7233140
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
    Bishop MC, Fellows GJ.
    Br J Urol; 1977 Feb 21; 49(7):711-6. PubMed ID: 597712
    [Abstract] [Full Text] [Related]

  • 8. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
    Gielen F, Dequeker J, Drochmans A, Wildiers J, Merlevede M.
    Br J Cancer; 1976 Sep 21; 34(3):279-85. PubMed ID: 974001
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL.
    J Urol; 1994 Apr 21; 151(4):909-13. PubMed ID: 7510346
    [Abstract] [Full Text] [Related]

  • 11. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y, Hasegawa K, Sugimura R, Otomo S, Morii H.
    Endocrinol Jpn; 1974 Apr 21; 21(2):109-13. PubMed ID: 4408206
    [No Abstract] [Full Text] [Related]

  • 12. Hydroxyproline as a marker for following patients with metastatic prostate cancer.
    O'Brien WM, Lynch JH.
    J Urol; 1988 Jan 21; 139(1):66-8. PubMed ID: 3121868
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Urinary hydroxyproline excretion in patients with cancer.
    Guzzo CE, Pachas WN, Pinals RS, Krant MJ.
    Cancer; 1969 Aug 21; 24(2):382-7. PubMed ID: 5796782
    [No Abstract] [Full Text] [Related]

  • 16. Serum osteocalcin concentration in patients with prostatic cancer.
    Francini G, Bigazzi S, Leone V, Gennari C.
    Am J Clin Oncol; 1988 Aug 21; 11 Suppl 2():S83-7. PubMed ID: 3266542
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Excretion of urinary hydroxyproline in urinary tract diseases].
    Guarino A, Comar OB, Taccone W, Cicalese V.
    Arch Sci Med (Torino); 1979 Aug 21; 136(2):249-54. PubMed ID: 92978
    [Abstract] [Full Text] [Related]

  • 19. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
    Stĕpán JJ, Mikulecký M, Bek V, Broulík P, Pacovský V.
    Neoplasma; 1989 Aug 21; 36(4):495-501. PubMed ID: 2770935
    [Abstract] [Full Text] [Related]

  • 20. Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.
    Mundy AR.
    Br J Urol; 1979 Dec 21; 51(6):570-4. PubMed ID: 534843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.